Evaluation of Psychopathologies and Health-Related Quality of Life in Patients With Macular Amyloidosis. / [Artículo traducido] Evaluación de psicopatologías y calidad de vida relacionada con la salud en pacientes con amiloidosis macular.

Macular amyloidosis (MA) is a skin condition with predominance in young women. We aimed to evaluate quality of life (QoL) and psychopathologies in these patients. In this cross-sectional study, patients with MA referring to the Imam Reza Hospital, Mashhad during 2018-2020, and their matched controls were included. Participants completed the 36-item short form survey (SF-36), the revised symptom checklist-90 (SCL-90-R), and the dermatology life quality index (DLQI). Overall, 40 women with a mean age of 36.80±10.19 years were studied. In the MA group, the SF-36 score was lower (P<0.001), and the SCL-90-R score was higher (P<0.001). The DLQI score was correlated with age (r=0.447; P=0.048) and pruritus severity (r=0.776; P<0.001), and was lower in patients with uncovered lesions (P=0.005). MA was associated with impaired QoL, which was determined by pruritus severity and lesion location; these patients can benefit from psychiatric interventions in this regard.

Evaluation of Psychopathologies and Health-Related Quality of Life in Patients With Macular Amyloidosis.

Macular amyloidosis (MA) is a skin condition with predominance in young women. We aimed to evaluate quality of life (QoL) and psychopathologies in these patients. In this cross-sectional study, patients with MA referring to the Imam Reza Hospital, Mashhad during 2018-2020, and their matched controls were included. Participants completed the 36-item short form survey (SF-36), the revised symptom checklist-90 (SCL-90-R), and the dermatology life quality index (DLQI). Overall, 40 women with a mean age of 36.80±10.19 years were studied. In the MA group, the SF-36 score was lower (P<0.001), and the SCL-90-R score was higher (P<0.001). The DLQI score was correlated with age (r=0.447; P=0.048) and pruritus severity (r=0.776; P<0.001), and was lower in patients with uncovered lesions (P=0.005). MA was associated with impaired QoL, which was determined by pruritus severity and lesion location; these patients can benefit from psychiatric interventions in this regard.

Evaluation of Psychopathologies and Health-Related Quality of Life in Patients With Macular Amyloidosis / Evaluación de psicopatologías y calidad de vida relacionada con la salud en pacientes con amiloidosis macular

Macular amyloidosis (MA) is a skin condition with predominance in young women. We aimed to evaluate quality of life (QoL) and psychopathologies in these patients. In this cross-sectional study, patients with MA referring to the Imam Reza Hospital, Mashhad during 2018–2020, and their matched controls were included. Participants completed the 36-item short form survey (SF-36), the revised symptom checklist-90 (SCL-90-R), and the dermatology life quality index (DLQI). Overall, 40 women with a mean age of 36.80±10.19 years were studied. In the MA group, the SF-36 score was lower (P<0.001), and the SCL-90-R score was higher (P<0.001). The DLQI score was correlated with age (r=0.447; P=0.048) and pruritus severity (r=0.776; P<0.001), and was lower in patients with uncovered lesions (P=0.005). MA was associated with impaired QoL, which was determined by pruritus severity and lesion location; these patients can benefit from psychiatric interventions in this regard (AU)

La amiloidosis macular (AM) es una situación cutánea con predominancia en mujeres jóvenes. Nuestro objetivo fue evaluar la calidad de vida (QoL) y las psicopatologías en estos pacientes. En este estudio transversal se incluyó a pacientes con AM derivados al Hospital Imam Reza, de Mashhad, de 2018 a 2020, así como a sus controles pareados. Los participantes completaron la encuesta SF-36 (formulario breve de 36 ítems), el test de los 90 síntomas revisado (SCL-90-R) y el índice de calidad de vida en dermatología (DLQI). A nivel global, se estudió a 40 mujeres con una edad media de 36,80±10,19 años. En el grupo AM, la puntuación SF-36 fue más baja (p<0,001), siendo más alta la puntuación SCL-90-R (p<0,001). La puntuación DLQI se correlacionó con la edad (r=0,447; p=0,048) y con la severidad del prurito (r=0,776; p<0,001), siendo más baja en las pacientes con lesiones sin cubrir (p=0,005). La AM estuvo asociada a un deterioro de la QoL, que vino determinada por la severidad del prurito y la localización de la lesión. A este respecto, dichas pacientes pueden beneficiarse de intervenciones psiquiátricas (AU)

[Artículo traducido] Evaluación de psicopatologías y calidad de vida relacionada con la salud en pacientes con amiloidosis macular / Evaluation of Psychopathologies and Health-Related Quality of Life in Patients With Macular Amyloidosis

La amiloidosis macular (AM) es una situación cutánea con predominancia en mujeres jóvenes. Nuestro objetivo fue evaluar la calidad de vida (QoL) y las psicopatologías en estos pacientes. En este estudio transversal se incluyó a pacientes con AM derivados al Hospital Imam Reza, de Mashhad, de 2018 a 2020, así como a sus controles pareados. Los participantes completaron la encuesta SF-36 (formulario breve de 36 ítems), el test de los 90 síntomas revisado (SCL-90-R) y el índice de calidad de vida en dermatología (DLQI). A nivel global, se estudió a 40 mujeres con una edad media de 36,80±10,19 años. En el grupo AM, la puntuación SF-36 fue más baja (p<0,001), siendo más alta la puntuación SCL-90-R (p<0,001). La puntuación DLQI se correlacionó con la edad (r=0,447; p=0,048) y con la severidad del prurito (r=0,776; p<0,001), siendo más baja en las pacientes con lesiones sin cubrir (p=0,005). La AM estuvo asociada a un deterioro de la QoL, que vino determinada por la severidad del prurito y la localización de la lesión. A este respecto, dichas pacientes pueden beneficiarse de intervenciones psiquiátricas (AU)

Macular amyloidosis (MA) is a skin condition with predominance in young women. We aimed to evaluate quality of life (QoL) and psychopathologies in these patients. In this cross-sectional study, patients with MA referring to the Imam Reza Hospital, Mashhad during 2018–2020, and their matched controls were included. Participants completed the 36-item short form survey (SF-36), the revised symptom checklist-90 (SCL-90-R), and the dermatology life quality index (DLQI). Overall, 40 women with a mean age of 36.80±10.19 years were studied. In the MA group, the SF-36 score was lower (P<0.001), and the SCL-90-R score was higher (P<0.001). The DLQI score was correlated with age (r=0.447; P=0.048) and pruritus severity (r=0.776; P<0.001), and was lower in patients with uncovered lesions (P=0.005). MA was associated with impaired QoL, which was determined by pruritus severity and lesion location; these patients can benefit from psychiatric interventions in this regard (AU)